openPR Logo
Press release

Pulmonary edema Market - Market Growing at a Healthy Rate | 2019

Pulmonary edema Market

Pulmonary edema Market

Pulmonary edema is considered a leading cause of deaths among cardiovascular diseases. The global market for pulmonary edema is chiefly driven by the rising prevalence of cardiac attacks and other associated diseases, changing lifestyles of the global population, extensive research and development activities, and an increased awareness about preventive therapies.

The report on the global pulmonary edema market presents a detailed account of the various factors affecting the overall growth, factors restraining growth, trends, and other important factors shaping the market.

Utilizing industry-leading research tools and techniques, the pulmonary edema market report serves as an excellent guide to market strategies, ensuring effective financial planning, investment modeling, expansion in new market segments, and monitoring the market’s competitive landscape. With the rising prevalence of cardiovascular diseases across the globe, the outlook for the markets for therapeutic methodologies, medicines, and other related markets pertaining to the field of cardiovascular diseases is promising.

Obtain Report Details @ http://www.transparencymarketresearch.com/pulmonary-edema-market.html

Overview of the Global Pulmonary Edema Market

The WHO states that across the world, nearly 82% of the 38 million deaths caused by non-communicable diseases (NCDs) in 2012 were due to one of the following four NCDs - cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes. Of these, the leading cause of deaths was the segment of cardiovascular diseases, resulting in nearly 17.5 million deaths, or a 46.2% share of NCD deaths.

A large portion of these deaths occurred due to pulmonary edema, a condition which leads to impaired gas exchange and may also lead to respiratory failure due to fluid accumulation in parenchyma and air spaces of lungs. A major causative agent responsible for pulmonary edema is the failure of the left ventricle of the heart, while an injury to the lungs is also a chief reason leading to the condition.

Make an Enquiry @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2250

The global market for pulmonary edema presents a detailed account of the chief diagnostic technologies, therapeutic methods, and key regional markets. Diagnostic technologies consist of ECG, x-ray, renal and liver function tests, and blood tests for electrolyte concentration. Therapeutic methods for pulmonary edema include emergency management techniques such as antibiotics for lung infection-induced pulmonary edema, natural or mechanical ventilation, respiratory distress agents such as morphine, antipyretics for minimizing pain, and loop diuretics.

While the global pulmonary edema market has huge growth prospects, it will have to face restraints such as the high cost required in R&D activities and government austerity towards specification of therapeutic products.

Leading Companies in the Global Pulmonary Edema Market

The report presents a detailed discussion of financial health, recent developments, SWOT analysis, and other information on a variety of industry verticals of some of the key businesses in the market. Also included is a detailed account of activities of medical research universities engaged in research and development activities of pulmonary edema therapeutic products. These include MayoClinic, Synvista Therapeutics includes, Inc., University of Heidelberg, Hopitaux Universitaires de Gene ve, and University of Oxford, among others.

About Us:-

Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers.

We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us:-

Transparency Market Research

90 State Street, Suite 700, Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Visit Blog: http://marketresearchreports2017.blogspot.in

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pulmonary edema Market - Market Growing at a Healthy Rate | 2019 here

News-ID: 718564 • Views:

More Releases from Transparency Market Research - Pharmaceutical

Neurovascular Devices Market Business Opportunities and Growth Challenges Report
Neurovascular Devices Market Business Opportunities and Growth Challenges Report
Global Neurovascular Devices Market: Overview The global population is aging rapidly. According to WHO, the chances of health risks are greater in geriatric people than the young generation. Old age is considered to be one of the biggest risk factors that are responsible for developing various diseases such as cardiovascular and neurological conditions. It is because of these factors, the global neurovascular devices market is experiencing robust growth in the
Pneumococcal Vaccines Market anticipated expand at a CAGR of 3.3% from 2018 to 2026
Pneumococcal Vaccines Market anticipated expand at a CAGR of 3.3% from 2018 to 2 …
Transparency Market Research (TMR) has published a new report titled, “Pneumococcal Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global pneumococcal vaccines market was valued at US$ 7,247.6 Mn in 2017 and is anticipated expand at a CAGR of 3.3% from 2018 to 2026. Increase in patient pool, growth of the pharmaceutical industry, government initiatives to increase vaccination programs, rise
Swab and Viral Transport Medium Market projected to expand at a CAGR of ~3% from 2020 to 2030
Swab and Viral Transport Medium Market projected to expand at a CAGR of ~3% from …
Swab and Viral Transport Medium Market: Introduction Transparency Market Research has published a new report titled, ‘Global Swab and Viral Transport Medium Market ’. According to the report, the global swab and viral transport medium market was valued at US$ 0.9 Bn in 2019 and is projected to expand at a CAGR of ~3% from 2020 to 2030. Viral transport medium (VTM) enables safe transfer of viruses, chlamydia, and mycoplasma for
Radiofrequency Ablation Devices Market by Product, Geography and Forecast to 202 …
Transparency Market Research (TMR) has published a new report titled, 'Radiofrequency Ablation Devices for Pain Management Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027'. According to the report, the global radiofrequency ablation devices for pain management market was valued at US$ 543.0 Mn in 2018 and is projected to expand at a CAGR of above 11.0% from 2019 to 2027. Overview Radiofrequency ablation is a minimally invasive surgical

All 5 Releases


More Releases for Pulmonary

Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027. Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion. Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated
Pulmonary Embolism - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Pulmonary Embolism - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Embolism - Pipeline Review, H2 2017, provides an overview of the Pulmonary Embolism (Cardiovascular) pipeline landscape. Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood
Pulmonary Drugs 2024 Market Research Report
Global Pulmonary Drugs Market: Snapshot The global pulmonary drugs market has been the key area of focus and the most crucial market for the healthcare industry in the last couple of years. However, the market is expected to witness a significant decline over the forecast period with a -6.3% CAGR from 2016 to 2024. The market is anticipated to fall to US$28,082.1 mn from a valuation of US$48,039.7 mn in
03-15-2017 | Health & Medicine
TMR
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments